{"id":251502,"date":"2021-08-12T00:00:00","date_gmt":"2021-08-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidid0035-biopharma-human-immunodeficiency-virus-epidemiology-4\/"},"modified":"2026-03-31T10:42:41","modified_gmt":"2026-03-31T10:42:41","slug":"epidid0035-biopharma-human-immunodeficiency-virus-epidemiology-americas","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidid0035-biopharma-human-immunodeficiency-virus-epidemiology-americas\/","title":{"rendered":"Human Immunodeficiency Virus &#8211; Epidemiology &#8211; Americas"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of human immunodeficiency virus (<abbr title=\"human immunodeficiency virus\">HIV<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and total prevalence of <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> therapy forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> per year?<\/li>\n<li>How will improvements in survival change the number of people living with <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases.<\/li>\n<li>Total prevalent cases.<\/li>\n<li>Total prevalent cases by diagnosis.<\/li>\n<li>Diagnosed prevalent cases by treatment (mature pharmaceutical markets only).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-251502","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-human-immunodeficiency-virus","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251502\/revisions"}],"predecessor-version":[{"id":283933,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251502\/revisions\/283933"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}